

**nature  
medicine**

## 1999 Subject index • Volume 5

<b>No. 1</b>	1–123	<b>No. 7</b>	713–849	(NV)	News & Views
<b>No. 2</b>	125–243	<b>No. 8</b>	851–961	(L)	Letter to the Editor
<b>No. 3</b>	255–356	<b>No. 9</b>	963–1087	(C)	Commentary
<b>No. 4</b>	357–464	<b>No. 10</b>	1089–1214	(NT)	New Technology
<b>No. 5</b>	465–590	<b>No. 11</b>	1215–1328	(Corr)	Correction
<b>No. 6</b>	591–711	<b>No. 12</b>	1329–1457	(Err)	Errata

- A**
- A $\beta$ , See Amyloid  $\beta$  peptide
- Ac-YVAD-cmk, caspase inhibition, neural graft survival, 97
- Academic health centers, biomedical research squeeze, 472(N)
- Academic Medicine Development Company, 6(N)
- Acute myeloid leukemia  
AML1 Runt domains, 1356(NV)  
CD44-targeted differentiation therapy, 619(NV), 669
- Adeno-associated virus  
 $\alpha$ V $\beta$ 5 integrin co-receptor, 78, 467(L)  
fibroblast growth factor receptor 1 co-receptor for, 71, 467(L)
- Adeno-associated virus vector  
factor IX gene delivery, hemophilia B, 21 (NV), 56, 64  
purification, 587  
re-targeting of, genetic capsid modifications, 1052, 1438(Err)  
sarcoglycan delivery, 439
- Adenosine 5'-diphosphate, P2Y1 receptor mediation of, 1199
- Adenosine triphosphohydrolase, hemostasis and thrombosis modulation, 987(NV), 1010
- Adenoviral vectors  
instability during transport, clinical implications, 955(NT)  
tissue-specific immune response, cardiac transplant implications, 1143  
glioma therapy, chronic inflammation induction, 1237(NV), 1256
- Adenovirus E1A, Ewing fusion transcript EWS/FLI2 induction, 991(NV), 1076
- Advanced sleep phase syndrome, 983(NV), 1062
- Ag<sup>+</sup>-resistant determinant, 183
- Age-related macular degeneration, FasL role, subretinal angiogenesis, 292
- Aging research center opens, 1338(N)
- AIDS-Kaposi's sarcoma, IL-4 toxin treatment, 738(NV), 817
- AIDS progression, SIV *in vivo* evolution role, 488(NV), 535
- AIDS vaccine, See HIV-1 vaccine
- AIDS Vaccine Research Center, director appointed, 362(N)
- Alcoholic cirrhosis, tumor necrosis factor- $\alpha$  role, 1243(NV)
- Allegheny University of the Health Sciences bankruptcy, 130(N)
- Allergy protection, oral gene delivery, 380(NV), 387
- Allografts, See Transplantation
- $\alpha$ -cardiac myosin heavy chain mutation, heart failure, 266(NV), 327
- $\alpha$ -galactosidase A enhancement, Fabry lymphoblasts, 112
- $\alpha$ -tropomyosin mutants, calcium-sensitization, hypertrophic cardiomyopathy, 1413
- $\alpha$  $\beta$ -crystallin, and intermediate filaments, 25(NV)
- $\alpha$ V $\beta$ 5 integrin, adeno-associated virus 2 co-receptor, 78
- ALPS II genetic analysis, 876(NV)
- Altered peptide ligands, T-cell priming interference, 565
- Alzheimer disease  
amyloid- $\beta$  vaccine, 870(NV)  
diagnostic test conflict-of-interest problems, 717(N)  
neuronal excitotoxic necrosis, PS-1 knock-in mice, 101  
presenilin mutations,  $\beta$ -catenin trafficking, 149(NV), 164  
presenilin mutations, transgenic mice, 560  
PS-1 exon 9 deletion defined, 1090(L)
- Amacrine cells, and myopia, 879(NV)
- AML1 Runt domain mutations, 1356(NV)
- Amyloid  $\beta$  peptide, Alzheimer disease vaccine, 870(NV)
- Amyloid plaques, and PS1 mutations, transgenic mice, 560
- Amyotrophic lateral sclerosis  
creatine neuroprotective effects, 347  
lack of apoptosis, mice, 966(L)
- Ancient Andean people, ancestry, HTLV-I, 1357(NV), 1428
- Androgen receptor, HER-1/neu crosstalk, prostate cancer, 264(NV), 280
- Angiogenesis  
and bone formation, VEGF role, 617(NV), 623  
endothelial progenitor cells, 434  
FasL role, retina, 292  
NSAIDs inhibition of, mechanisms and implications, 1348(NV), 1418  
suppression of, tumor-host interactions, gallbladder, 1203  
targeted pro-apoptotic peptides, cancer, 1032
- VEGF isoforms potential use, 491(NV), 495
- Angiogenic growth factors, clinical applications, 1359(R)
- Angiopoietins, 1359(R)
- Angiotensin converting enzyme inhibitors, 1110(C)
- Animal rights, US universities offer courses, 973(N)
- Antibiotic resistance, 147(NV), 358(L)
- Antigen-presenting cells, See Dendritic cells
- Antigen-specific immunosuppression, 'killer' dendritic cells, 930
- Anti-inflammatory therapy, thymosin  $\beta$ 4 mechanism, 1424
- Anti-tumor therapy, See Cancer therapy; Cancer vaccine
- Anxiety, GABA<sub>A</sub> receptor, mouse model, 1131(NV)
- APC mutation type, disease severity mechanism, 1071
- APEC Technomart III conference, 1338(N)
- ApolipoproteinA-I/HDL metabolism, cubulin receptor, 656
- Apoptosis, See also Neuronal apoptosis  
activated T cells, tumor-associated antigen, 874(NV), 938  
alloreactive T cells, transplant tolerance induction, 1231(NV), 1298, 1303  
amyotrophic lateral sclerosis, mice, 966(L)  
Bax protein inhibition of, 832  
caspase inhibitor effects, 97, 298  
environmental enrichment prevention of, 448  
magnetic resonance spectroscopy tumor lipid detection implications, 1323(NT)  
and NF- $\kappa$ B inhibition of, 412  
p53 independent mechanism, atherosclerosis, 335  
targeted peptides, angiogenesis toxicity, cancer, 1032
- Apoptosis-linked gene 4 (ALG-4), FasL regulation, 542
- Arthritis  
bacterial DNA CpG motifs, 702  
See also Rheumatoid arthritis  
Ascorbic acid transporters, 620(NV)  
Asialo-IFN- $\gamma$ , hepatitis B inhibition, 577
- Aspirin, angiogenesis inhibition mechanism, 1348(NV), 1418
- Asthma,  $\gamma$  $\delta$  T cells role, 1127(NV), 1150
- Atelocollagen, plasmid DNA delivery, 707(NT)
- Atherosclerosis  
CD40-CD154 interactions, 1313  
cholesteryl ester transfer protein role, 1383  
p53 inactivation effect, 335

## INDEX

- Atypical measles, immunopathology, 629
- Australia
- bioethics guidelines consolidation, 973(N)
  - biomedical research budget increase, 598(N)
  - cloning report examined by parliament, 1098(N)
  - doctoral student drop-out problem, 721(N)
  - genome research facility lack of funding, 366(N)
  - primate center proposal, 133(N)
  - research papers high citation rates, 254(N)
  - tertiary education Green Paper, 859(N)
  - 'Wills Report' research review, 9(N)
- Autoimmune diseases
- bisindolylmaleimide therapy, 19(NV), 42
  - CD8 cells epitope identification, Type 1 diabetes, 992(NV), 1026
  - green fluorescent protein gene transfer, T cells, 843(NT)
  - inhibition of, 19(NV), 42, 90, 1346(NV), 1375
  - multiple sclerosis autoantibody identification, 153(NV), 170
  - NIH Office legislation, 972(N)
  - serum amyloid P component protective effect, 607(NV), 694, 852(L)
- Autoimmune lymphoproliferative syndrome, 876(NV)
- Autoimmune T cells
- green fluorescent protein gene transfer, brain, 843(NT)
  - neuroprotective role, 28(NV), 49
- Autonomic circuits, obesity role, 742(NV)
- Azodicarbonamide, T-cell response inhibition, 947
- B**
- B7 family, 1345(NV)
- B7-H1, 1345(NV), 1365
- Bacterial arthritis, DNA CpG motifs, 702
- Bacterial meningitis, caspase inhibitor neuroprotection, 298
- The Baltimore case, 13(B)
- Basal cell carcinoma, *Ptch* knockout mice, 1285
- Bax protein, virus-induced neuronal apoptosis inhibition, 832
- $\beta$ -catenin trafficking, presenilin mutations, Alzheimer disease, 149(NV), 164
- $\beta$ -galactosidase-Tat fusion protein, 1133(NV)
- $\beta$ 1 integrin, chemotherapy resistance role, lung cancer, 662
- $\beta$ 2 integrin, ICAM binding, neutrophil phagocytosis potentiation, 231
- $\beta$  tumor cell metastasis, NCAM reduced expression, 286
- Bioethics
- Australia harmonizes guidelines, 973(N) and Chinese genetics, 247(L)
  - Declaration of Helsinki review, 1094(N)
  - WHO staff appointment, 1094(N)
- Bioinformatics, NIH priority, 719(N)
- Biosamples report, US bioethics commission, 974(N)
- Bisindolylmaleimide, autoimmune disease therapy, 19(NV), 42
- Bitter taste receptors, cloning, 381(NV)
- Bleeding time, P2Y<sub>1</sub>-deficient mice, 1199
- Blobel, Günter, 1230(N)
- Blood, history of medicine and commerce, 258(B)
- Blood pressure, prostaglandin EP<sub>2</sub>-deficient mice, 217
- Body weight regulation
- mahogany* gene relevance, 374(NV)
  - neuropeptide Y Y2 receptor role, 1188
- Bolognesi, Dani, 362(N)
- Bone formation, VEGF role, 617(NV), 623
- Bone marrow transplantation, osteogenesis imperfecta, 262(NV), 309, 466(L)
- Bone regeneration, plasmid gene delivery, polymer matrix, 733(NV), 753
- Books reviewed
- The Baltimore Case*, 13
  - Blood; an Epic History of Medicine and Commerce*, 258
  - Born That Way; Genes, Behavior, Personality*, 259
  - The Brain and Emotion*, 605
  - Cardiology: The Evolution of the Science and the Art*, 1229
  - Chemokines and Cancer*, 865
  - Dendritic Cells: Biology and Clinical Applications*, 979
  - Designing Babies: The Brave New World of Reproductive Technology*, 605
  - The Development of Human Gene Therapy*, 728
  - The Devil's Workshop*, 1343
  - Early Warning: Cases and Ethical Guidance for the Presymptomatic Testing of Genetic Diseases*, 372
  - Has Feminism Changed Science?*, 729
  - Heart Development*, 260
  - A History of Molecular Biology*, 140
  - The Human Eye: Structure and Function*, 1229
  - Infections and Inequalities: The Modern Plagues*, 727
  - Judging Science: Scientific Knowledge and the Federal Courts*, 979
  - Memory: From Mind to Molecules*, 1343
  - The Molecules Within Us*, 480
  - Of Flies, Mice and Men*, 13
  - Opioids in Pain Control: Basic and Clinical Aspects*, 371
  - Phantoms in the Brain: Probing the Mysteries of the Human Mind*, 139
  - The Rise and Fall of Modern Medicine*, 865
  - The River: A Journey to the Source of HIV and AIDS*, 1117
  - The Sceptical Witness*, 980
  - Scientific American Molecular Neurology*, 479
  - Textbook of Gene Therapy*, 371
  - Tissue Engineering of Vascular Prosthetic Grafts*, 1118
  - Transcription Factors and Human Disease*, 481
  - Viruses and Human Cancer*, 479
  - What Remains To Be Discovered: Mapping the Secrets of the Universe, the Origins of Life and the Future of the Human Race*, 258
- Borrelia burgdorferi, 1346(NV), 1375
- BP 897, cocaine addiction therapy, 993(NV)
- Brain stem cells, differentiation, 261(NV)
- Brain tumors, oncolytic virus therapy and cyclophosphamide, rats, 881
- Breast cancer, hematopoietic stem cell transplantation, 1243(NV)
- Bristol Myers Squibb
- African AIDS initiative, 599(N)
  - Distinguished Achievement Awards, 9
- Brundtland, Gro Harlem, 249(N)
- Busquin, Philippe, 1096(N)
- C**
- C5a blockade, sepsis treatment, 788
- Calcineurin, and heart failure, 246(L)
- Calcium channel blockers, rod photoreceptor rescue, retinitis pigmentosa, 1183
- Calcium
- dilated cardiomyopathy role, 1353(NV)
  - hypertrophic cardiomyopathy role, mutant  $\alpha$ -tropomyosin effect, 1413
  - and mtDNA oxidative phosphorylation deficiency, 951
- Calpain 3 deficiency, limb-girdle muscular dystrophy type 2A, 439, 503, 849(Err)
- Canada
- clinical trial approval time shortened, ethics, 1336(N)
  - research funds increase, 251(N)
  - spending spree to end 'brain drain', 1336(N)
  - xenotransplantation research activity, 361(N)
- Cancer Research Campaign, tobacco money stand, 125(E), 129(N)
- Cancer therapy
- dendritic cell-NK cell cross-talk, 405
  - FasL counterattack, 267(NV)
  - NF- $\kappa$ B inhibition, 412
  - NSAIDs angiogenesis inhibition, 1348(NV), 1418
  - oncolytic viruses and cyclophosphamide, 881
  - pro-apoptotic peptides, angiogenesis targeting, 1032
  - Ras downregulation, 989(NV)
  - RCAS1 tumor-associated antigen role, 938
  - telomerase reverse transcriptase target, 1129(NV), 1164
  - tumor necrosis factor- $\alpha$  neutralization, 828
- Cancer vaccine
- antigen-presenting cell modulation, 780
- CD40-stimulation component, 774
- clinical trials design strategies, 1124(NV), 1171
  - naked, self-replicating RNA, 823
  - patient specificity plus granulocyte-monocyte colony stimulating factor, 1124(NV), 1171
- Cannabinergic pain modulatory system, 1243(NV)
- Capsid modifications, adeno-associated virus re-targeting, 1052, 1438(Err)
- Carcinogenesis, natural selection role, 11(C)
- Cardiac failure
- $\alpha$ -cardiac myosin heavy chain mutation, 266(NV), 327
  - and calcineurin, 246(L), 266(NV)
  - enterovirus protease 2A dystrophin cleavage, 266(NV), 320
  - intracellular calcium role, 1353(NV)
  - prevention of, postmyocardial infarction, 1122(NV), 1135
  - VEGF isoforms potential use, 491(NV), 495

- Cardiac function, nitric oxide synthase modulation of, 273(NV), 331
- Cardiac imaging, functional, 237(NT)
- Cardiac myocytes  
 $\alpha$ -tropomyosin-induced calcium sensitization, 1413  
 nitric oxide synthase role, 273(NV), 331
- Cardiac pressor agents, hemodynamics, 1241(NV)
- Cardiac rupture prevention, 1122(NV), 1135
- Cardiac transplantation  
 adenovirus-mediated gene transfer value, 1143  
 passenger leukocytes and microchimerism function, 1292
- Cardiology, 1229(B)
- Cardiomyopathy  
 $\alpha$ -cardiac myosin heavy chain mutation, 266(NV), 327  
 calcineurin role, 246(L), 266(NV)  
 enterovirus protease 2A dystrophin cleavage, 266(NV), 320
- Cardiovascular 'orphan' G protein receptor agonists, physiology, 1241(NV)
- Cargo processing, endoplasmic reticulum, 745(R)
- Caspase inhibition  
 bacterial meningitis neuroprotection, 298  
 nigral transplants increased survival, 97
- Caspase-3  
 apoptotic cascade activation, spinal cord trauma, 943  
 HIV-1 gene therapy, 27(NV), 29
- Caspases, ALPS II genetic analysis, 876(NV)
- Cathepsin C, periodontal infection protective role, 1358(N)
- CCR5 co-receptor  
 allo-immunization downregulation of, 1004  
 biochemical properties, and HIV fusion, 303, 590(Err)  
 HIV T-cell cytopathology, 344, 592(L)  
 inhibitors of, HIV evolution danger, 740(NV), 1091(L)
- CD4<sup>+</sup> cells, See also HIV-specific CD4<sup>+</sup> cells  
 azodicarbonamide inhibition of, 947  
 CD40 priming of, tumor vaccine enhancement, 780  
 cytomegalovirus US2 protein effect on, 1039  
 green fluorescent protein gene transfer, brain, 843(NT)  
 stress-induced experimental colitis role, 1178
- CD8<sup>+</sup> cells, See also HIV-specific CD8<sup>+</sup> cells  
 antigen-specific unresponsiveness, tumors, 677  
 CD40 priming, anti-tumor vaccine augmentation, 774  
 epitope identification, type I diabetes, 992(NV), 1026
- CD8 $\alpha\alpha$  receptor, cytotoxic T-cell antagonism, 399
- cd39-deficient mice, hemostasis and thrombotic reactions, 987(NV), 1010
- CD40  
 CD4<sup>+</sup> cell priming, anti-cancer vaccine augmentation, 780  
 CD154 interactions, atherosclerosis progression, 1313  
 CTL priming, anti-cancer vaccine augmentation, 774  
 lymphoma eradication, CD4<sup>+</sup> cell independence, 548
- CD44-targeted differentiation therapy, acute myeloid leukemia, 619(NV), 669
- CD47 ligation, chronic lymphocytic leukemia cell death induction, 1277
- CD95L cDNA-transfected 'killer' dendritic cells, immunosuppression, 930
- CD154  
 antibodies against, allograft rejection prevention, 616(NV), 686  
 atherosclerosis progression role, 1313
- Cell enrichment, 459(NT)
- Cellular xenotransplantation, 852(L), 855(N)
- Central nervous system  
 autoimmune T cells protective effect, 28(NV), 47  
 stem cell differentiation, 261(NV)
- Cerebral ischemia, See also Stroke  
 NAALADase inhibition neuroprotective effect, 1396  
 NF- $\kappa$ B role, 439, 503
- Chemokines, and cancer, 865(B)
- Chemoresistance  
 extracellular matrix protein role, lung cancer, 662  
 NF- $\kappa$ B role, 412
- Children's Vaccine Initiative, 469(N)
- Chimeric HIV-1 clones, PCR-mediated recombination, 237(NT)
- Chimpanzees  
 NIH program, 1217(L)  
 Quebec sanctuary conflict, 718(N)
- China  
 geneticists' ethical views, 247(L)  
 HIV research funding, 364(N)  
 HIV vaccine meeting, 1097(N)  
 research institutes reorganization, 857(N)  
 tobacco smoking epidemic, 15(NV)  
 US research collaboration solicited, 858(N)
- Chitosan-DNA oral gene delivery, peanut allergy protection, 380(NV), 387
- Cholesteryl ester transfer protein, proatherogenesis, 1383
- Chondrocyte hypertrophy, VEGF expression, bone formation, 617(NV), 623
- Chromatin, serum amyloid protein control of, 607(NV), 694
- Chromosome 22 sequenced, 1358(N)
- Chronic inflammatory disease, L-selectin mechanism, 1057
- Chronic liver disease, hepatitis B virus transgenic mouse model, 907
- Chronic lymphocytic leukemia, CD47 ligation effect, 1277
- Circadian rhythmicity  
 cocaine abuse link, 981(N)  
 inherited tendencies, advanced sleep phase disorder, 983(NV), 1062
- Cirrhosis, See Liver cirrhosis
- Clinical research, 477(C), 714(L), 853(L)
- CLOCK gene mutations, 983(NV), 1062
- Cluster headache, voxel-based morphometry, 732(NV), 836
- Cocaine addiction  
 circadian locomotor activity link, 981(N)  
 dopamine D3 receptor partial agonist therapy, 993(NV)
- Coffee studies, Vanderbilt University institute, 252(N)
- Coherent multiprobe fluorescence, 351(NT)
- Colon cancer suppression, MAP kinase inhibition effect, 736(NV), 810
- Colorectal cancer  
 mismatch repair signaling, 1339(NV)
- NSAIDs angiogenesis inhibition mechanism, 1348(NV), 1418
- Complement pathway inhibition, stroke damage reduction, 995(NV)
- Conflict-of-interest problems, 713(E), 717(N)
- Congenital heart defects prevention, *in utero* gene transfer, lambs, 141(NV), 176
- Cooperation and competition in research, 1329(E)
- 'Cornsweet effect', 1238(NV)
- Coronary heart disease  
 cholesteryl ester transfer protein role, rats, 1383  
 UK report, 600(N)
- COX 2  
 intestinal immune homeostasis role, 867(NV), 900  
 potential anti-inflammatory properties, 621(NV), 698
- COX-2 inhibitors, 1348(NV), 1418
- Coxsackievirus protease 2A, dystrophin cleavage, cardiomyopathy, 266(NV), 320
- CpG motifs, bacterial arthritis DNA, 702
- Creatine, amyotrophic lateral sclerosis neuroprotection, 347
- Cristofalo, Vincent, 130(N)
- Crozemarie, Jacques, 722
- Cubilin, epithelial apoA-I/HDL metabolism role, 656
- CXCR4 co-receptor  
 allo-immunization downregulation of, 1004  
 biochemical properties, and HIV fusion, 303, 590(Err)  
 and HIV entry inhibitors, 740(NV), 1091(L)  
 HIV T-cell cytopathology, 344, 592(L)
- Cyclooxygenase-2  
 intestinal immune homeostasis role, 867(NV), 900  
 potential anti-inflammatory properties, 621(NV), 698
- Cyclooxygenase inhibitors, 1348(NV), 1418
- Cyclophosphamide, and oncolytic virus therapy, 881
- Cyclosporin A, tumor progression link, 382(NV), 714(N)
- Cytokine therapy, neovascularization role, 434
- Cytomegalovirus US2 protein, CD4<sup>+</sup> cell evasion, 1039
- Cytotoxic T cells  
 CD40 priming, anti-tumor vaccine augmentation, 774  
 FasL expression, degranulation role, 19(NV), 90  
 lymphoma eradication, CD40-targeted therapy, 548  
 SIV 'escape' hypothesis, 1233(NV), 1270  
 soluble CD8 antagonism of, 399
- D**
- Dahl salt-sensitive hypertensive rats, 1383
- 'Danger hypothesis', 1232(NV), 1249
- Deferiprone controversy, 2(L), 7(N), 1223(N)
- Demyelinating disease  
 autoantibody identification, MS, 153(NV), 170  
 and hepatitis B vaccination, 964(L)
- Dendritic cells  
 biology and clinical applications, 979(B)  
 endogenous activators, 1232(NV), 1249

## INDEX

- immunosuppression induction, CD95L cDNA transfection, 930
- interferon production, precursors, 868(NV), 919
- NK cell anti-tumor response trigger, 405
- prion protein expression, scrapie, 1235(NV), 1308
- transplantation tolerance-inducing strategies, 1245(R)
- I-Deoxy-galactonojirimycin, 112
- Desmin-related myopathy, 25(NV)
- Developing countries, tobacco smoking epidemic, 15(NV)
- Dexter, Mike, 597(N)
- Diabetes mellitus
- miscarriage risk, 126(L)
- new academic center, Novo Nordisk investment, 250(N)
- orally active, insulin molecule identification, 615(NV)
- Diabetes mellitus, insulin-dependent
- CD8 T-cell epitope identification, insulin B chain, 992(NV), 1026
- NAD<sup>+</sup> depletion link, 269(NV), 314
- NOD mouse model, 601(C)
- and PARP inactivation, 269(NV), 314
- Diabetes Research Working Group, 364(N)
- Diabetic retinopathy, 1390
- Dideoxynucleoside resistance, MRP4 transporter role, 1048
- Dietary antigen, intestinal immune response, COX-2 role, 867(NV), 900
- DiGeorge syndrome, genetically engineered mouse model, 1120(NV)
- Dilated cardiomyopathy
- enterovirus protease 2A dystrophin cleavage, 266(NV), 320
- intracellular calcium role, 1353(NV)
- Diltiazem, rod photoreceptor rescue, retinitis pigmentosa, 1183
- DNA enzyme, Egr-1 mRNA targeting, 1264, 1438(Err)
- DNA microarrays. See Microarray technology
- DNA vaccination
- dangers, 126(L)
- immunodeficiency virus, 526
- tuberculosis, 872(NV)
- DNAVEC gene therapy, 2(L)
- Dopamine D3 receptor partial agonist, cocaine addiction therapy, 993(NV)
- Dopaminergic neurons
- graft survival, caspase inhibition, 97
- MPTP degenerative effects, iNOS role, 1354(NV), 1403
- Downless gene cloning, 870(NV)
- Drug resistance
- antibiotics, 147(NV), 358(L)
- nucleoside-based antiviral drugs, 1048
- Ductus arteriosus closure prevention, *in utero* gene transfer, 141(NV), 176
- Dystrophin cleavage, enterovirus protease 2A, cardiomyopathy, 266(NV), 320
- E**
- E2F, vein-graft decoy role, 1353(N)
- Early growth response factor-1 mRNA, DNA enzyme targeting of, 1264, 1438(Err)
- Eastman, Richard, 129(N), 254(Corr)
- Ebola virus resistance, immunologic determinants, 373(NV), 423
- Embryonic stem cells, See Human embryonic stem cells; Stem cells
- Emotions, and brain, 605(B)
- Endochondral ossification, vascular endothelial growth factor role, 617(NV), 623
- Endoplasmic reticulum signaling integration, 745(R)
- Endothelial progenitor cells, neovascularization role, 434
- Enterovirus protease 2A, dystrophin cleavage, cardiomyopathy, 266(NV), 320
- Env protein, amino acid variation, CTL escape, SIV, 1233(NV), 1270
- Environmental enrichment, 448
- Ependymal stem cells, adult brain, 261(NV)
- Epidemics, pathogen population dynamics, *Streptococcus*, 924
- Epigallocatechin-3-gallate, 1216(L)
- Epithelial cells, enrichment of, 459(NT)
- Erythropoietic protoporphyria, gene therapy long-term cure, mice, 768
- Estrogen, prolactin pathogenesis role, 1317
- Estrogen surface receptor, 1330(L)
- mitogen-activated protein kinase link, 1130(NV)
- Ethics, See Bioethics
- Ewing tumor fusion transcript EWS/FLI1, viral gene induction, 991(NV), 1076, 1331(L)
- Excitotoxic necrosis, PS1 knock-in mice, neurons, 101
- Experimental autoimmune encephalomyelitis, myelin damage, autoantibody identification, 53(NV), 170
- Experimental colitis, stress-induced reactivation, CD4<sup>+</sup> cells role, 1178
- Extracellular matrix proteins, chemotherapy resistance mechanism, 662
- The eye, structure and function, 1229(B)
- F**
- Fabry disease,  $\alpha$ -galactosidase A enhancement, 112
- Factor VIII, alloantibody proteolysis, hemophilia A, 1044
- Factor IX gene AAV delivery, hemophilia B, 21(NV), 56, 64
- Familial adenomatous polyposis, APC somatic mutation determinant, 1071
- Familial hypertrophic cardiomyopathy, See Hypertrophic cardiomyopathy
- Familial platelet disorder, 1356(NV)
- Fas ligand
- apoptosis-linked gene 4 regulation of, 542
- bisindolylmaleimide apoptosis facilitation, 19(NV), 42
- degranulation regulation of, 19(NV), 90
- subretinal angiogenesis control, 292
- tumor-infiltrating lymphocytes apoptosis induction, 267
- Febrile seizures, persistent neuronal modification, developing brain, 871(NV), 888
- Feeding behavior
- versus autonomic circuits, obesity, 742(NV)
- neuropeptide Y Y2 receptor role, 1188
- Feminism, influence on science, 729(B)
- Fertility, prostaglandin EP<sub>2</sub>-deficient mice, 217
- Fetal gene therapy, pros and cons, 245(E), 255, 256(C)
- Fetal immunization, baboons, 427
- Fibrinogen-coated albumin microparticles, thrombocytopenia treatment, rabbits, 17(NV), 107
- Fibroblast growth factor, prolactinoma pathogenesis, 1317
- Fibroblast growth factor receptor 1, adeno-associated virus 2 co-receptor, 71
- Fibronectin synthesis block, *in utero* gene transfer, heart defect prevention, 141(NV), 176
- Financial conflicts of interest, 713(E), 717(N)
- Finn2 Alzheimer disease pedigree, 1090(L)
- Fludarabine, STAT1 signaling inhibition, 444
- Food allergy protection, oral gene delivery, 380(NV), 387
- Food and Drug Administration
- research base strengthening, 133(N)
- UK blood donation ban, 720
- Forensic science, 980(B)
- Freedom of Information Act, 8(N)
- Friend virus vaccine, lymphocyte subset requirements, 189
- Functional cardiac imaging, 237(NT)
- G**
- GABA<sub>A</sub> receptor
- and anxiety, mouse model, 1131(NV)
- febrile seizure persistent modification, developing brain, 871(NV), 888
- temporal lobe epilepsy, 590(Err)
- Gallbladder tumors, transforming growth factor  $\beta$ 1 expression, 1203
- $\gamma\delta$  T cells, airway responsiveness downregulation, 1127(NV), 1150
- Gates, Bill, 857(N)
- Gene activated matrix, and gene therapy, bone regeneration, 733(N), 753
- Gene expression, microgravity conditions, 359(L)
- Gene mapping, cancer cells, 24(NV)
- Gene therapy
- adeno-associated virus capsid modifications, 1052, 1438(Err)
- congenital heart defect prevention *in utero*, 245(E), 255, 256(C)
- chronic brain inflammation induction, Adv/HSV-1-TK, 1237(NV), 1256
- development of, 728(B)
- erythropoietic protoporphyria, mice, 768
- germline risk, 245(E), 255, 256(C)
- hemophilia B, AAV factor IX gene delivery, 21(NV), 56, 64
- HIV protease target, 27(NV), 29
- in utero* pros and cons, 245(E), 255, 256(C)
- limb-girdle muscular dystrophy, 439
- liver cirrhosis, hepatocyte growth factor, 226
- peanut allergy protection, 380(NV), 387
- textbook, 371(B)
- Gene transfer
- fibronectin block, heart defect prevention, 141(NV), 176

- green fluorescent protein, brain-specific T cells, 843(NT)
- Genetic diseases, presymptomatic testing, 372(B)
- Genetic testing, British insurers, 974(N)
- Genome patenting, 1223
- George, Charles, 597(N)
- Geriatric cancer research, apathy in, 971(N)
- Germany
- new rules for academic professors, 974(N)
  - science funding cutbacks, 971(N)
  - science ministry increased budget, 253(N)
- Germline gene therapy, pros and cons, *in utero*, 245(E), 255, 256(C)
- Geron Bio-Med, 595(N)
- Glioma gene therapy
- chronic brain inflammation complication, 1256(NV), 1256
  - MRS lipid detection, apoptosis detection implications, 1323(NT)
- Global Alliance for Vaccines and Immunization, 1089(E)
- Glucocorticoids, anti-inflammatory mediators up regulation, 1424
- gp41 block, HIV entry inhibitor design, 1133(NV)
- Graft-versus-host disease, 839
- Grafts, See Transplantation
- Granulocyte–monocyte colony-stimulating factor, lymphoma vaccination, 1124(NV), 1171
- Green fluorescent protein gene transfer, 843(NT)
- Green tea, tumor invasion suppression, 1216(L)
- Group A *Streptococcus* epidemics, pathogen dynamics, 924
- H**
- HAART, See Highly active anti-retroviral therapy
- Headache, voxel-based morphometry, 732(NV), 836
- Heart defects, congenital, *in utero* gene transfer, 141(NV), 176
- Heart development, 260(B)
- Heart failure, See Cardiac failure
- Heart transplantation, See Cardiac transplantation
- Hematopoiesis, Runt domain role, 1356(NV)
- Hematopoietic stem cell transplantation, breast cancer, 1243(NV)
- Hemophilia A, factor VIII alloantibody proteolysis, 1044
- Hemophilia B, adeno-associated virus factor IX gene delivery, 21(NV), 56, 64
- Hemostasis, *cd39*-deficient mice, 987(NV), 1010
- Henney, Jane, 133(N)
- Heparanase
- cloning and functional characterization, 735(NV), 793, 803
  - pro-metastatic role, 735(NV), 793, 803
- Hepatitis B
- asialo-IFN- $\gamma$  inhibition of, 577
  - immune response, animal models, 907, 1125(NV)
  - transgenic mouse model, liver disease, 907
- Hepatitis B vaccination
- baboons, *in utero*, 426
  - demyelinating disease incidence, 964(L)
- Hepatitis B virus transgenic mouse model, chronic liver disease, 907
- Hepatocyte growth factor, liver cirrhosis gene therapy, 226
- HER-2/neu, androgen receptor cross-talk, prostate cancer, 264(NV), 280
- Hereditary non-polyposis colorectal cancer, mismatch repair signaling, 1239(NT)
- High-density lipoprotein endocytosis, cubulin receptor, 656
- Highly active anti-retroviral therapy
- CD4<sup>+</sup> cells latent infection, 512, 518, 609(NV)
  - interleukin-2 combination therapy, 611(NV), 651
  - ongoing HIV dissemination, 1099(C)
  - resistance to, MRP4 transporter, 1048
  - T-cell production systems focus, 27(NV), 83
- Hippocampal neurons
- apoptosis prevention, meningitis, 298
  - excitotoxic necrosis, PS-1 knock-in mice, 101
- HIV-1 CCR5 co-receptor, See CCR5 co-receptor
- HIV-1 chimeric clones, PCR-mediated recombination, 237(NT)
- HIV-1 CXCR4 co-receptor, See CXCR4 co-receptor
- HIV-1 entry inhibitors
- gp41 targeting, 1133(NV)
- HIV virulence increase danger, 740(NV), 1091(L), 1330(L)
- HIV-1 infection
- CTL 'escape' hypothesis, 1233(NV), 1270
  - CXCR4/CCR5 biochemical properties link, 303
  - lifelong persistence, CD4<sup>+</sup> cells, 512
- HIV-1 Nef protein, See Nef protein
- HIV-1 pathogenesis
- CD4<sup>+</sup> production systems focus, 27(NV), 83
  - and immune response evasion, 723(C)
  - in vivo* evolution role, 488(NV), 535
- HIV-1 protease, gene therapy target, 27(NV), 29
- HIV-1 replication
- allo-immunization effect, 1004
  - persistence of, 723(C)
  - SAM68 mutants inhibition of, 635, 849(Err)
  - virus-specific CTLs role, 27(NV), 34
- HIV-specific CD4<sup>+</sup> cells
- adoptive transfer, HIV treatment potential, 27(NV), 34
  - allo-immunization strategy, infectivity decrease, 1004
  - CCR5- and CXCR4-trophic HIV cytopathology, 344
  - directly measured kinetics, 27(NV), 83
- HAART therapy limits, 483(NV), 512, 518, 609(NV)
- HIV 'hideout' role, 1358(N)
- interleukin-1-HAART combination therapy, 611(NV), 651
- latent infection persistence, 483(NV), 512, 518, 609(NV)
- Nef protein chemotaxis and activation mediation, macrophage role, 985(NV), 997
- production/destruction controversy, 27(NV), 83
- HIV-specific CD8<sup>+</sup> cells
- adoptive transfer, treatment potential, 27(NV), 34
  - allo-immunization effect, 1004
  - directly measured kinetics, 27(NV), 83
- HIV-1 Tat protein vaccine induction of, 612(NV), 643
- HIV-1 Tat protein
- blood–brain barrier permeability, 1133(NV)
  - vaccine use, 612(NV), 643
- HIV-1 therapy, See also Highly active anti-retroviral therapy
- cytotoxic T cell adoptive transfer, 27(NV), 34
- gene therapy approach, 27(NV), 29
- resistance to, MRP4 transporter, 1048
- T-cell production systems focus, 27(NV), 83
- HIV-1 vaccine
- allo-immunization strategy, 1004
  - Beijing meeting, 1097(N)
  - DNA priming and recombinant pox virus, 526
- HIV replication persistence challenge, 723(C)
- IAVI research initiative, 5(N)
  - live attenuated SIV prototype, risk, 154(NV), 194
  - SHIV DH12-specific neutralizing antibodies, 142(NV), 204, 211
  - South African plans, 252(N)
  - Tat protein use, 612(NV), 643
- Holt-Oram syndrome, 853(L)
- Hospital for Sick Children, deferiprone controversy, 2(L), 7(N)
- HTLV-1 provirus DNA, Andean mummy, 1428
- Human cloning research
- public mistrust, 10(N)
  - Roslin Institute reports, 253(N)
- Human embryonic stem cells
- Italian clamp-down, 720
  - politics, ethics, and medical progress, 1339(C)
  - potential applications, 151(NV), 975(C)
  - research ban, scientists appeal, 6(N)
  - therapeutic cloning, 975(C)
  - UK government indecision, 855(N)
  - US debate heats up, 366(N)
- Human Frontier Science Program, 7(N)
- Human genome sequencing, rivals square off, 471(N)
- Human research, ethical standards, 591(E)
- Human T-cell lymphotropic virus type I provirus DNA, Andean mummy, 1428
- Huntington disease, lymphoblast apoptosis, mitochondrial depolarization, 1194
- Hyperlipidemia, cholesteryl ester transfer protein role, rats, 1383
- Hypertension
- cholesteryl ester transfer protein role, rats, 1383
  - prostaglandin EP<sub>2</sub>-deficient mice, 217
- Hyperthermia-induced seizures, persistent neuronal modification, developing brain, 871(NV), 888
- Hypertrophic cardiomyopathy
- $\alpha$ -cardiac myosin heavy chain mutation, 266(NV), 327
  - $\alpha$ -tropomyosin-induced calcium sensitization, 1413
  - calcineurin role, 246(L), 266(NV)
- I**
- ICAM- $\beta$ , integrin binding, neutrophil phagocytosis potentiation, 231
- I $\kappa$ B $\alpha$ /NF- $\kappa$ B pathway, limb-girdle muscular dystrophy, 439, 503, 849(Err)
- Immune 'interference' effect, 565
- Immunoglobulin A nephropathy prevention, uteroglobin role, mice, 1018
- Immunology research, US lead threatened, 471(N)
- Immunosuppressive drugs, design of, 1243(NV)
- In utero* gene therapy, pros and cons, 245(E), 255, 256(C)

# INDEX

- In utero* immunization, baboons, 427
- India  
 animal activists delay primate trial, 1098(N)  
 appeal to expatriate neuroscientists, 1222(N)  
 vaccine development program, 970(N)  
 World Bank backs AIDS program, 1096(N)
- Infertility, prostaglandin EP<sub>2</sub>-deficient mice, 217
- Inflammatory response suppression, L-selectin mechanism, 1057
- Influenza A virus, 484(NV)  
 China as origin of, 384(NV)  
 vaccine development, 1119(NV), 1157
- Ingelfinger rule, 357(E)
- Institute for Global Health, 860(N)
- Institute for Molecular Oncology, 973(N)
- Insulin, orally active, small molecule identification, 614(NV)
- Insulin B chain autoantigen identification, type I diabetes, 992(NV), 1026
- Insulin-dependent diabetes mellitus. See Diabetes mellitus, insulin-dependent
- Insulin-like growth factor-I receptor, VEGF relationship, retinal neovascularization, 1390
- Integrins, ICAM binding, neutrophil phagocytosis potentiation, 231
- Interferon type I, plasmocytoid monocyte production of, 868(NV), 919
- Interleukin-1 receptor, mental retardation role, 1133(NV)
- Interleukin-4 toxin, AIDS-Kaposi's sarcoma treatment, 738(NV), 817
- Interleukin-10, B1-H1 stimulation of, 1345(NV), 1365
- Intermediate filaments, small heat shock protein chaperone requirement, 25(NV)
- International AIDS Vaccine Initiative, 5(N)
- Intestinal immune response, COX-2 role, 867(NV), 900
- Intracytoplasmic sperm injection, 377(NV), 431, 593(L), 1133(NV)
- Ion channels, 1105(C)
- Ireland, National Cancer Institute agreement, 1221(N)
- Ischemic brain injury, NAALADase inhibition neuroprotective effect, 1396
- Ischemic cardiomyopathy, VEGF isoforms potential use, 491(NV), 495
- Ischemic tissue neovascularization, endothelial progenitor cells, 434
- Istituto Superiore della Sanità, 858(N), 967(L)
- Italian National Research Council reform, 132(N)
- Italy  
 biotechnology industry rebuff, 363(N)  
 fertility research clamp-down, 720(N)
- Institute for Molecular Oncology, 973(N)  
 private research funding challenge, 135(C)  
 rare diseases increased focus, 472(N)  
 research institute decree, 858(N), 967(L)  
 university spending monitoring groups created, 1222(N)
- Ito, Yoichi, 474(N)
- J**
- Japan  
 biomedical research reorganization, 365(N)
- clinical trial numbers boost, 860(N)  
 cloning regulators criticized, 1221(N)  
 experimental tissue regulation, 473(N)  
 first xenotransplantation conference, 1335(N)  
 influenza vaccinations, 592(N)  
 "Millennium Project," 1095(N)  
 Science and Technology Basic Plan debate, 597(N)  
 obacco tragedy, 1091
- Joint inflammation downregulation, L-selectin mechanism, 1057
- Joint Infrastructure Fund, biomedical benefits, 596(N)
- K**
- Kaposi's sarcoma, IL-4 toxin treatment, 738(NV), 817
- Kidney development, 22(NV)
- Kidney transplants  
 NIAID begins clinical tolerance trials, 470(N)  
 rejection prevention, antibodies against CD154, 616(NV), 686
- "Killer" dendritic cells, immunosuppression, 930
- Knock-in PSI mice, neuron excitotoxic necrosis vulnerability, 101
- Knudson's 'two-hit' hypothesis, 1071
- L**
- Laser capture microdissection, 117(NT)
- Lasker Awards, 1105, 1110, 1113
- Latent HIV-1 infection, 512
- Leech neurons, dynamic computer calculations, 722(N)
- Lep expression, tissue-specific autoregulation, 895
- Leptin  
 neuropeptide Y Y2 receptor role, 1188  
 obesity role, 742(NV)  
 tissue-specific Lep regulation, 895
- Leukemic blast cells, CD44-targeted differentiation therapy, 619(NV), 669
- Limb-girdle muscular dystrophy, 439, 503, 849(Err)
- Lincoln, Abraham, DNA access denied, 859(N)
- Lipopolysaccharide resistance, Toll-like receptor mutations, 144(NV)
- Live attenuated vaccines
- lymphocyte subset requirements, Friend virus, 189
- multiply deleted SIV risk, 154(NV), 194, 590(Err)
- Liver cirrhosis, hepatocyte growth factor gene therapy, 226
- Liver disease, See Chronic liver disease
- Long-extension PCR, dangers in the clinic, 965(L)
- Luminance perception, 1238(N)
- Lyme disease, autoantigen and T-cell epitopes identification, 1346(NV), 1375
- Lymphoblast apoptosis, Huntington disease, mitochondrial depolarization, 1194
- Lymphoma  
 CD40-targeted therapy, 548  
 patient-specific vaccination plus GM-CSF, 1124(NV), 1171
- Lymphotoxin pathway blockade, virus-induced shock reversal, 1370
- properties, fusion, 303, 590(Err)
- Magnetic resonance imaging, neuronal fiber tracking, 1133(NV)
- Magnetic resonance spectroscopy, tumor lipid detection, apoptosis detection implications, 1323(NT)
- Mahogany* cloning, obesity application, 374(NV)
- Malaria  
 European Commission decision surprise, 1333(N)  
 immunity development, 272(NV), 340
- Medicines for Malaria Venture critics, 1334(N)  
 vaccine future, Europe, 969(N)  
 Wellcome Trust report, 1334(N)
- Malawi, Africa, research center, 253(N)
- MAP kinase inhibition, tumor growth suppression, 736(NV), 810
- Marijuana, US research policy shift, 721(N)
- MART-1-specific T cells, characterization, 677
- Matrix metalloproteinase-inhibitor TIMP-1, 1122(NV), 1135
- MCP Hahnemann University, 130(N)
- Mdm2, Arf control of, 490(NV)
- Measles immunopathology, 629
- Mechanical ventilation, neural control, 1433(NT)
- Medical journalism, 357(E)
- Medical records, US ruling, research implications, 1337(N)
- Medicines for Malaria Venture, 1334(N)
- Melanocortin response, POMC-null mice, obesity, 984(NV), 1066
- Melanoma, tumor-associated antigen-specific T cells, 677
- Mental illness, and brain science, 1113(C)
- Mental retardation, IL-1 receptor role, 1133(NV)
- MERRF mutation, mitochondrial calcium signaling, 951
- Mesenchymal stem cells, osteogenesis imperfecta therapy, 262(NV), 309, 466(L)
- Methicillin-resistant *Staphylococcus aureus*, 147(NV)
- Microarray technology, and laser capture microdissection, 117(NT)
- Microchimerism, allograft acceptance functional relevance, 1292
- Microgravity cultures, gene expression, 359(L)
- Minipellet plasma DNA delivery system, 707(NT)
- Minor histocompatibility antigen-specific CTLs, graft-versus-host disease, 839
- Minority groups  
 cancer research criticism, 254(N)  
 neuroscience research, 600(N)
- Mismatch repair signaling, tumor development, 1239(NV)
- Mitochondrial depolarization, lymphoblast apoptosis, Huntington disease, 1194
- Mitochondrial DNA disorders  
 calcium signaling defect, 951  
 mouse model, 957
- Mitogen-activated protein kinase  
 estrogen surface receptor link, 1130(NV)  
 inhibition of, tumor suppression, 736(NV), 810
- MOG-specific autoantibodies, multiple sclerosis mechanism, 153(NV), 170
- Molecular biology, history, 140(B)
- Molecular medicine, 477(C), 714(L)
- Molecular mimicry, chronic Lyme disease, 1346(NV), 1375

- Monocytes, HIV-1 fusion, CXCR4 biochemistry, 303, 590(Err)
- Morphine, in pain control, 371(B)
- Mouse model, mitochondrial DNA disease, 957
- MPTP Parkinson disease model, iNOS knockout mice, 1354(NV), 1403
- Multiple-primer-induced overlapping amplification assay, 1081(NT)
- Multiple sclerosis, myelin damage, autoantibody identification, 153(NV), 170
- Mycobacterium tuberculosis*, antibiotic resistance, 358(L)
- Myelin basic protein-specific T cells, 28(NV), 49
- Myelin oligodendrocyte glycoprotein autoantibodies, MS, 153(NV), 170
- Myocardial angiogenesis, VEGF isoforms potential use, 491(NV), 495
- Myocardial infarction, cardiac rupture prevention, 1122(NV), 1135
- Myopia, 879(NV)
- N**
- NAALADase inhibition, ischemic brain injury protection, 1396
- NAD<sup>+</sup> depletion, type I diabetes role, 269(NV), 314
- Naked RNA vaccine, cancer therapy, 823
- Narcolepsy, 981(N)
- NARP mutation, mitochondrial calcium signaling, 951
- National Cancer Institute, minority group research, criticism, 254(N)
- National Health Service research collaboration, 473(N)
- National Heart Forum report, 600(N)
- National Institutes of Health (US)
- bioinformatics priority, 719(N)
  - conflict-of-interest investigation, 129(N), 254(Corr)
  - grant system overhaul proceeds, 1219(N)
  - PhD plan dropped, 1098(N)
  - PhD program established, 719(N)
  - public input, benefits of, 1097(N)
  - social science research importance, 600(N)
  - transplant tolerance project, 1222(N)
- Natural killer cells
- FasL expression, degranulation role, 19(NV), 90
  - dendritic cells trigger of, antitumor response, 405
- Natural selection, tumorigenesis role, 11(C)
- nef*-deleted SIV vaccine, 154(NV), 194
- Nef protein
- amino acid variation, CTL escape, SIV, 1233(NV), 1270
  - HIV-1 macrophage infection, lymphocyte chemotaxis and activation, 985(NV), 997
- Neovascularization, endothelial progenitor cells, 434
- Nephrin gene, 22(NV)
- Neural apoptosis
- Bax inhibition of, 832
  - caspase inhibitor prevention, meningitis, 298
  - environmental enrichment preventive effect, 448
- NMDA receptor blockade, 270(NV)
- Neural cell adhesion molecule,  $\beta$  tumor cell metastasis role, 286
- Neural grafts, apoptosis reduction, caspase inhibition, 97
- Neural regeneration, 734(NV)
- Neural stem cell differentiation, adult brain, 261(NV)
- Neuropeptide Y2 receptor, body weight and food intake regulation, 1188
- Neuroprotective benefits, autoimmune T cells, 28(NV), 49
- Neutrophil phagocytosis potentiation, ICAM- $\beta_2$  integrin binding, 231
- Neutrophils, L-selectin shedding, inflammatory response suppression, 1057
- Nevirapine use hurdles, developing countries, 1093
- New York encephalitis virus mystery, 1243(NV)
- NF- $\kappa$ B
- cell death promotion, cerebral ischemia, 554
  - chemoresistance role, 412
  - limb girdle muscular dystrophy, 439, 503
- Nigral transplants, apoptosis reduction, caspase inhibition, 97
- Nitric oxide synthase
- cardiac function modulation, 273(NV), 331
  - and MPTP Parkinson disease model, knockout mice, 1354(NV), 1403
- NMDA receptor blockade, neural apoptosis, perinatal brain, 270(NV)
- No-consent trials, 250(N)
- Non-obese diabetic mouse model, 601(C)
- Nonsteroidal anti-inflammatory drugs, angiogenesis inhibition mechanism, 1348(NV), 1418
- Novartis Pharma, academic research funding expanded, 1337(N)
- Novo Nordisk, academic research investment, 250(N)
- Nucleoside-based antiviral drug resistance, MRP4 role, 1048
- O**
- Obesity
- autonomic circuits versus feeding, 742(NV)
  - and *mahogany* gene cloning, 374(NV)
  - melanocortin response, POMC-null mice, 984(NV), 1066
- Ogden, Russel, 1224(N)
- Olefsky, Jerrold, 1098(N)
- Olivieri, N., 2(L), 7(N), 1223(N)
- Oncogene-specific therapeutics, Ras downregulation, 989
- Oncolytic virus therapy, and cyclophosphamide, 881
- Opioids, in pain control, 371(B)
- Optic nerve injury, autoimmune T cells protective effect, 28(NV), 49
- Oral polio vaccine/AIDS hypothesis, 1117(B)
- Oral tolerance, COX-2 role, 867(NV), 900
- Orally active insulin molecule, 614(NV)
- Orexins, 981(N)
- Organ transplantation, See Transplantation
- 'Orphan' G protein-coupled receptor agonists, cardiovascular physiology, 1241(NV)
- Orthogonal polarization spectral imaging, 1209(NT)
- Osteogenesis, Runt domain role, 1356(NV)
- Osteogenesis imperfecta, mesenchymal stem cell therapy, 262(NV), 309, 466(L)
- Ovarian carcinoma, RCAS1 tumor-associated antigen role, 874(NV), 938
- Oxford International Biomedical Centre, 363(N)
- P**
- P2Y<sub>1</sub>-deficient mice, ADP-induced platelet effects, 1199
- p<sup>16INK4a</sup> senescence gene, rheumatoid arthritis treatment, 731(NV), 760
- p53 inactivation, atherogenesis role, 335
- Papillon-Lefevre syndrome, 1358(N)
- Passenger leukocytes, allograft acceptance function, 1292
- Pancreatic beta-cell destruction, PARP inactivation effect, 269(NV), 314
- Pancreatic beta tumor cell metastasis, NCAM reduced expression, 286
- Parkinson disease
- MPTP model, iNOS knockout mice, 1354(NV), 1403
  - neural graft survival, caspase inhibition, 97
  - thalamocortical "dysrhythmias," 1349(NV)
- PARP deficiency, type I diabetes resistance, 269(NV), 314
- Patched* inactivation, basal cell carcinoma tumorigenesis, 1285
- PCR-mediated recombination, HIV-1 chimeric clones, 237(NT)
- Peanut allergy protection, oral gene delivery, 380(NV), 387
- Periaqueductal gray, pain modulation, 1243(NV)
- Peridontal infection, cathepsin C protective role, 1358(N)
- Personality, genetics, 259(B)
- Pesticide testing, humans, US subcommittee indecision, 972(N)
- 'Phen-fen' diet drugs, conflict-of-interest lawsuit, 717(N)
- Pituitary tumor transforming gene, prolactinoma pathogenesis, 1317
- Plasmacytoid monocytes, type I interferon production, 868(NV), 919
- Plasmid DNA
- bone regeneration therapy, 733(NV), 753
  - delivery system, 707(NT)
- Plasminogen activator inhibitor-1, cardiac rupture prevention, 1122(NV), 1135
- Platelet substitutes, thrombocytopenia treatment, 17(NV), 107
- Platelets
- cd39-deficient mice, 987(NV), 1010
  - P2Y<sub>1</sub>-deficient mice, 1199
- Pluripotent stem cells, See Stem cells
- Pneumococcal meningitis, caspase inhibitor neuroprotection, 298
- POMC-null mice, melanocortin response, obesity, 984(NV), 1066
- Population-based epidemiological research, 853(L)
- Population growth, 1215(E)
- Porcine endogenous retrovirus, FDA xenotransplants report, 855(N)
- Potassium channel, 1105(C)
- pp32 species, prostate cancer modulation, 264(NV), 275
- Precursor dendritic cells, interferon production, 868(NV), 919
- Presenilin 1 knock-in mice, neuron excitotoxic necrosis vulnerability, 101
- Presenilin mutations
- accelerated neurodegeneration, transgenic mice, 560
  - $\beta$ -catenin trafficking, Alzheimer disease, 149(NV), 164
- Presidential DNA, access denied, 859(N)
- President's Advisory Council on HIV/AIDS, 1220(N)
- PREST report, 131(N)

- Prion protein, follicular dendritic cell production, 1235(NV), 1308
- Prion replication, 486(NV)
- Pro-apoptotic peptides, angiogenesis targeting, cancer, 1032
- Progressive subcortical gliosis, *tau* gene mutation, 454
- Prolactinoma pathogenesis, 1317
- Pro-opiomelanocortin null mice, melanocortin response, obesity, 984(NV), 1066
- Prostaglandin EP<sub>2</sub>-deficient mice  
reduced fertility, 217  
salt-sensitive hypertension, 217
- Prostate cancer  
HER-2/neu-androgen receptor cross-talk, 264(NV), 280  
modulation by pp32 alternate species, 264(NV), 275, 1087(Corr)
- Protein chaperones, and intermediate filament structural integrity, 25(NV)
- Pseudomonas aeruginosa*, vaccine strategy, 378(NV), 392
- Ptch* knockout mice, basal cell carcinoma tumorigenesis, 1285
- Public relations, 357(E)
- Pulmonary hemostasis,  $\gamma\delta$  T cells role, 1127(NV), 1150
- R**
- Radionuclide (Ta-178) ventriculography, 237(NT)
- C-raf* antisense, anti-tumor activity-correction, 127(L)
- Randomized controlled clinical trials database, 1224(N)
- RANTES, HIV allo-immunization effect, 1004
- Rare diseases, Italy's increased focus on, 472(N)
- Ras downregulation, oncogene specific therapy, 989
- RCAS1 tumor-associated antigen, 874(NV), 938
- Reactive oxygen species, thalidomide teratogenicity, 489(NV), 582, 715(L)
- Recombinant pox virus immunization, immunodeficiency virus challenges, 526
- Renal transplants  
NIAID begins clinical tolerance trials, 470(N)  
rejection prevention, antibodies against CD154, 616(NV), 686
- Reproductive technology, 605(B)
- Research assessment exercise (RAE) score, 251(N)
- Research ethics, See Bioethics
- Retinal neovascularization  
FasL control of, 292  
IGF-I and VEGF receptors relationship, 1390
- Retinitis pigmentosa, diltiazem rod photoreceptor rescue, 1183
- Retinoid acid pre-treatment, UV irradiation damage prevention, 376(NV), 418, 849(Err)
- Retroviruses, live attenuated vaccine design, 189
- Rev protein, Sam68 synergy, HIV-1 replication, 635, 849(Err)
- RG57, TNF- $\alpha$  upregulation of, sepsis, 877(NV), 913
- Rheumatoid arthritis, p<sup>16INK4a</sup> senescence gene treatment, 731(NV), 760
- Rho-associated kinase, tumor cell invasion role, 221
- RNA anti-tumor vaccine, 823
- ROCK protein kinases, tumor cell invasion role, 221
- Roizman, Bernard, 9(N)
- Roslin Bio-Med, 595(N)
- Roslin Institute, human cloning reports, 253(N)
- Ross, Russell, 475(Obit)
- Rotating wall vessel, 359(L)
- Runt domain, 1356(NV)
- S**
- Salmonella*, silver resistance molecular basis, 183
- Salt-sensitive hypertension, PGE<sub>2</sub> EP<sub>2</sub> receptor, 217
- Sam68 mutants, HIV-1 inhibition, 635,849(Err)
- San Raffaele Institute, 135(C)
- Sarcoglycan complex restoration, AAV vector, 439
- SCA8 expansion, 383(NV)
- Schistosome infection, acquired immunity development, 1225(C)
- Schizophrenia, Novartis Pharma research funding, 1337(N)
- sCR1sLex hybrid molecule, stroke treatment, 995(NV)
- Scrapie pathogenesis, follicular dendritic cells role, 1235(NV), 1308
- Seizure prevention, environmental enrichment link, 448
- L-selectin, inflammatory response downregulation mechanism, 1057
- Selection mechanism, tumorigenesis, 11(C)
- Senescence gene p<sup>16INK4a</sup>, rheumatoid arthritis treatment, 731(NV), 760
- Sepsis  
treatment of, C5a blockade, 788  
tumor necrosis factor-induced CNS changes, 877(NV), 913
- Septic arthritis, bacterial DNA CpG motifs, 702
- Septicemia, Toll-like receptor role, 144(NV)
- Serum amyloid P component, 607(NV), 694, 852(L)
- Shanghai Institutes for Biological Sciences, 857(N)
- Signal hypothesis, 1230(N)
- Silver resistance, *Salmonella* molecular basis, 183
- Simian immunodeficiency virus (SIV)  
CTL 'escape' hypothesis, 1233(NV), 1270  
HIV-1 Tat protein vaccine protection, 612(NV), 643  
*in vivo* evolution, AIDS progression, 488(NV), 535
- Simian immunodeficiency virus vaccine  
envelope-specific antibodies, HIV-1/SIV chimeric virus, 142(NV), 204, 211  
live attenuated form, risk, 154(NV), 194, 590(Err)
- Sin nombre virus, 1370
- Skin carcinogenesis, tumor necrosis factor- $\alpha$  role, 828, 1087(Err)
- Sleep  
circadian rhythm genetics, 983(NV), 1062  
tumor necrosis factor role, sepsis, 877(NV), 913
- Small cell lung cancer, chemotherapy resistance mechanism, 662
- Small heat shock protein chaperone mutations, 25(N)
- Smallpox stocks, research focus, 474(N)  
The SNP Consortium, 471(N)
- South Africa  
HIV treatment decision, pregnant women, 1(E)  
HIV vaccine grants awarded, 1220(N)  
HIV vaccine initiative, 252(N)
- South African Medical Research Council, 367(C)
- Spain  
new cancer research center, 722(N)  
researchers reject xeno-moratorium, 361(N)
- 'Spanish' flu virus, 384(NV), 484(NV), 1351(NV)
- Spinal cord injury  
caspase-3 apoptotic cascade activation, 943  
transplanted stem cell effects, rats, 1410
- Spinal cord regeneration, 734(NV)
- Spinocerebellar ataxia-8 expansion, 383(NV)
- Stanford University, cross-disciplinary biomedical research gift, 1338(N)
- STAT1 inhibition, fludarabine role, 444
- Steady-state cultures, gene expression, 359(L)
- Stem cells, See also Human embryonic stem cells  
differentiation in adult brain, 261(NV)  
osteogenesis imperfecta therapy, 262(NV), 309  
politics, ethics, and medical progress, 1339(C)  
spinal cord transplantation, rats, 1410  
transplantation of, breast cancer, 1243(NV)
- Streptococcus* epidemics, pathogen dynamics, 924
- Streptozocin-induced diabetes, 269(NV), 314
- Stress-induced experimental colitis reactivation, CD4<sup>+</sup> cells role, 1178
- Stroke  
complement cascade inflammatory response, inhibition of, 995(NV)  
NAALADase inhibition neuroprotective effect, 1396  
NF- $\kappa$ B role, 439, 503  
Stromelysin-1 repression, Tet-induced transformation, 990(NV)
- Substantia nigra, See Nigral transplants
- Sweet taste receptors, cloning, 381(NV)
- Systemic lupus erythematosus, serum amyloid P component protective effect, 607(NV), 694, 852(L)
- T**
- T cells, See CD4<sup>+</sup> cells; CD8<sup>+</sup> cells  
apoptosis of, transplantation tolerance induction, 1231(NV), 1298, 1303  
autoimmunity inhibition, BIS VIII, 19(NV), 42  
epitope identification, Lyme disease, 1346(NV), 1375  
FasL expression regulation, 19(NV), 90  
HIV tropism, CXCR4 biochemistry, 303  
neuroprotective role, 'benign autoimmunity', 28(NV), 49  
priming interference, altered peptide ligands, 565  
proliferation of, B7-H1 co-stimulation, 1345(NV), 1365
- Ta-178 radionuclide ventriculography, 237(NT)
- Taste receptors, cloning, 381(NV)
- TAT-Casp3 protein, 27(NV), 29
- Tat protein  
blood-brain barrier permeability, 1133(NV)  
HIV-1 vaccine, 612(NV), 643
- Tau* mutation, progressive subcortical gliosis, 454
- Telomerase inhibition, human cancer cell death, 1129(NV), 1164
- Temporal lobe epilepsy, GABAA receptor expression, 590(Err)
- Tenureship controversy, German professors, 974
- Tetracycline-induced transformation, stromelysin-1 repression, 990(NV)
- Thailand  
AIDS drug trials, 1217(L)  
animal welfare regulation, 722(N)



- Thalamocortical rhythms, neurological disorders, 1349(NV)
- Thalidomide, teratogenic mechanism, 489(NV), 582, 715(L), 853(L)
- Thrombocytopenia, platelet substitutes show promise, 17(NV), 107
- Thromboembolism resistance, P2Y<sub>1</sub>-deficient mice, 1199
- Thromboregulation, cd39-deficient mice, 987(NV), 1010
- Thymosin  $\beta$ 4 sulfoxide, anti-inflammation mechanism, 1424
- Tissue engineering, and gene therapy, bone regeneration, 733(NV), 753
- TNF-related apoptosis-inducing ligand, tumoricidal activity, 146(NV), 157
- Tobacco control  
increased activity, 851(E)  
settlement fund spending on, States, 1096(N)  
UK, EU, and US activity, 16(NV)  
World Bank report, 596(N)
- Tobacco money, Cancer Research Campaign stand, 125(E), 129(N)
- Tobacco settlement  
cancer centers interest, US, 10(N)  
and State spending, 1096(N)
- Tobacco smoking  
growing epidemic, 15(NV)  
Japan's tragedy, 1091(L)  
Toll-like receptor mutations, lipopolysaccharide resistance, 144(NV)
- Trachoma, antibiotic treatment modeling, 492(NV), 572
- TRAIL (TNF-related apoptosis-inducing ligand), tumoricidal activity, 146(NV), 157
- Transforming growth factor  $\beta$ 1, angiogenesis and tumor suppression, 1203
- Transplantation  
embryonic nigral tissue, caspase inhibition, 97  
embryonic stem cells, spinal cord injury, 1410  
NIAID clinical tolerance trials begin, 470(N)  
NIH tolerance induction project, 1222(N)  
passenger leukocytes and microchimerism function, 1292  
renal allografts, rejection prevention, 616(NV), 686  
tolerance induction, T-cell apoptosis, 1231(NV), 1298, 1303  
tolerance mechanisms, 1245(R)
- Traumatic spinal cord injury, caspase-3 apoptotic cascade activation, 943
- Trichoblastomas, *ptch* knockout mice, 1285
- Trinucleotide expansions, and spinocerebellar ataxia-8, 383(NV)
- Tuberculosis  
death and resurrection, 872(NV)  
DNA vaccine utility, 872(NV)  
and inequality, 727(B)
- Tumor-associated antigen-specific T cells, 677
- Tumor cell invasion  
heparanase function, 735(NV), 793, 803  
Rho-associated kinase role, 221
- Tumor growth suppression  
green tea role, 1216(L)  
transforming growth factor  $\beta$ 1, gallbladder, 1203
- Tumor-infiltrating lymphocytes, apoptosis induction, FasL expression, 267
- Tumor maintenance and regression, Ras mutation model, 989(NV)
- Tumor metastasis  
heparanase function, 735(NV), 793, 803  
Rho-associated kinase role, 221
- Tumor necrosis factor- $\alpha$   
alcohol damage role, 1243(NV)  
RGS7 upregulation, sepsis, 877(NV), 913  
kin carcinogenesis role, 828, 1087(Err)
- Tumor necrosis factor-related apoptosis-inducing ligand, 146(NV), 157
- Tumorigenesis, natural selection role, 11(C)
- 'Two-hit' hypothesis, familial adenomatous polyposis, 1071
- Type 1 diabetes, See Diabetes mellitus, insulin-dependent
- Type 1 interferon, plasmacytoid monocyte production of, 868(NV), 919
- Tyrosinase-specific T cells, 677
- U**  
*UFD1L* mutations, DiGeorge syndrome, 1120(NV)  
Uganda, AIDS reduction lessons, 963(E), 1217(L)  
Ultraviolet irradiation, retinoic acid pre-treatment effect, 376(NV), 418, 849(Err)
- University of Minnesota  
AIDS drug suit settlement, 1224(N)  
cocaine grant money repayment, 721(N)
- Urotensin-II, 1241(NV)
- Uterine carcinoma, RCAS1 tumor-associated antigen role, 874(NV), 938
- Uteroglobin, immunoglobulin a nephropathy prevention, mice, 1018
- V**  
Vaccination  
baboons, *in utero*, 427  
childhood safety, Congressional hearings, 970(N)
- Vaccine development, See also Cancer vaccine; HIV-1 vaccine  
global coalition, 249(N)  
global initiatives, 1089(E)  
India, 970(N)  
R&D investment value, 469(N)  
Varmus, Harold, 1219(N)
- Vascular endothelial growth factor  
bone formation role, 617(NV), 623  
clinical applications, 1359(R)  
retinal neovascularization regulation by IGF-1 receptor, 1390  
re-vascularization potential, isoforms, 491(NV), 495
- Vascular prosthetic grafts, tissue engineering, 1118(B)
- Vasoconstrictor agents, hemodynamics, 1241(NV)
- Viral genes, Ewing tumor fusion transcript induction, 991(NV), 1076
- Viral vector purification, 587(NT)
- Virus-induced shock reversal, lymphotoxin pathway blockade, 1370
- Viruses, and human cancer, 479(B)
- Vitamin A deficiency, UV irradiation effect, prevention, 376(NV), 418, 849(Err)
- Vitamin C transporters, 620(NV)
- VITIT peptide, 1243(NV)
- Voxel-based morphometry, cluster headache, 732(NV), 836
- vpr-deleted SIV vaccine, 154(NV), 194
- W**  
WASp function, 1128(NV)
- Wellcome Trust  
African research center, 253(N)  
biomedical research strategy, 861(C)  
genome-sequencing facilities potential sites, 1097(N)  
malaria research report, 1334(N)  
researcher salary increase, 597(N)
- Wikler, Dan, 1094
- William H. Gates Foundation, 857(N)
- 'Wills Report', 9(N)
- Wiskott-Aldrich syndrome, 1128(NV)
- Women  
doctorates increase, American universities, 1337(N)  
HIV allo-immunization, 1004
- World Conference on Science, 859
- World Disasters Report 1999, 860(N)
- World Medical Association, medical research guidelines revision, 598(N)
- X**  
Xenogeneic cells, 852(L), 855(N)
- Xenotransplantation  
Canadian research activity, 361(N)  
cellular level, 852(L)  
FDA findings, PERV transmission, 855(N)  
Japan hosts conference, 1335(N)  
Spanish researchers reject moratorium, 361(N)  
US guidelines, 476(E)  
WHO hosts Web discussion, 595(N)
- Z**  
Ziagen patent lawsuit settlement, 1224(N)